Bay­er, Ori­on prostate can­cer drug de­lays spread of dis­ease in PhI­II, but can it make a mark in a crowd­ed mar­ket?

Bay­er and Fin­land’s Ori­on (ORN­BV: $FH) on Wednes­day said their prostate can­cer drug, daro­lu­tamide, met the main goal in a late-stage tri­al, lift­ing Ori­on’s shares …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER